Italy: anti-diabetes drugs revenue 2018-2028

The revenue in the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market in Italy was forecast to continuously increase between 2024 and 2028 by in total 0.2 billion euro (+24.39 percent). After the tenth consecutive increasing year, the indicator is estimated to reach 0.99 billion euro and therefore a new peak in 2028. Notably, the revenue of the 'Anti-Diabetes Drugs' segment of the pharmaceuticals market was continuously increasing over the past years.

Find further information concerning the indicator 'revenue ' in the pharmaceuticals market in Italy and the revenue in the 'Vaccines' segment of the pharmaceuticals market in Argentina.

The Statista Market Insights cover a broad range of additional markets.

Revenue of the anti-diabetes drugs industry in Italy between 2018 and 2028 (in billion euros)

Characteristic	Revenue in billion euros
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Citation formats